Literature DB >> 33954876

Mesenchymal Stem Cells for Cardiac Regeneration: from Differentiation to Cell Delivery.

Santosh Gupta1, Akriti Sharma1, Archana S1, Rama Shanker Verma2.   

Abstract

Mesenchymal stem cells (MSCs) are so far the most widely researched stem cells in clinics and used as an experimental cellular therapy module, particularly in cardiac regeneration and repair. Ever since the discovery of cardiomyogenesis induction in MSCs, a wide variety of differentiation protocols have been extensively used in preclinical models. However, pre differentiated MSC-derived cardiomyocytes have not been used in clinical trials; highlighting discrepancies and limitations in its use as a source of derived cardiomyocytes for transplantation to improve the damaged heart function. Therefore, this review article focuses on the strategies used to derive cardiomyocytes-like cells from MSCs isolated from three widely used tissue sources and their differentiation efficiencies. We have further discussed the role of MSCs in inducing angiogenesis as a cellular precursor to endothelial cells and its secretory aspects including exosomes. We have then discussed the strategies used for delivering cells in the damaged heart and how its retention plays a critical role in the overall outcome of the therapy. We have also conversed about the scope of the local and systemic modes of delivery of MSCs and the application of biomaterials to improve the overall delivery efficacy and function. We have finally discussed the advantages and limitations of cell delivery to the heart and the future scope of MSCs in cardiac regenerative therapy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac regenerative therapy; Cardiomyocytes; Cell delivery; Differentiation; Mesenchymal stem cells

Mesh:

Year:  2021        PMID: 33954876     DOI: 10.1007/s12015-021-10168-0

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  59 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Adipose tissue derived mesenchymal stem cells are better respondents to TGFβ1 for in vitro generation of cardiomyocyte-like cells.

Authors:  Anupama Kakkar; Sushmita Bose Nandy; Suchi Gupta; Balram Bharagava; Balram Airan; Sujata Mohanty
Journal:  Mol Cell Biochem       Date:  2019-06-21       Impact factor: 3.396

3.  Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.

Authors:  A J Friedenstein; R K Chailakhyan; N V Latsinik; A F Panasyuk; I V Keiliss-Borok
Journal:  Transplantation       Date:  1974-04       Impact factor: 4.939

4.  Cardiomyocytes can be generated from marrow stromal cells in vitro.

Authors:  S Makino; K Fukuda; S Miyoshi; F Konishi; H Kodama; J Pan; M Sano; T Takahashi; S Hori; H Abe; J Hata; A Umezawa; S Ogawa
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.

Authors:  Catalin Toma; Mark F Pittenger; Kevin S Cahill; Barry J Byrne; Paul D Kessler
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

6.  Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes.

Authors:  Sunil Rangappa; Chen Fen; Eng Hin Lee; Ariff Bongso; Eugene Kwang Wei Sim; Eugene Kwang Sim Wei
Journal:  Ann Thorac Surg       Date:  2003-03       Impact factor: 4.330

7.  Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy.

Authors:  Hye Jin Jin; Yun Kyung Bae; Miyeon Kim; Soon-Jae Kwon; Hong Bae Jeon; Soo Jin Choi; Seong Who Kim; Yoon Sun Yang; Wonil Oh; Jong Wook Chang
Journal:  Int J Mol Sci       Date:  2013-09-03       Impact factor: 5.923

8.  Mesenchymal Stem Cells: Time to Change the Name!

Authors:  Arnold I Caplan
Journal:  Stem Cells Transl Med       Date:  2017-04-28       Impact factor: 6.940

9.  Mesenchymal stem cells.

Authors:  A I Caplan
Journal:  J Orthop Res       Date:  1991-09       Impact factor: 3.494

Review 10.  Shattering barriers toward clinically meaningful MSC therapies.

Authors:  Oren Levy; Rui Kuai; Erika M J Siren; Deepak Bhere; Yuka Milton; Nabeel Nissar; Michael De Biasio; Martina Heinelt; Brock Reeve; Reza Abdi; Meshael Alturki; Mohanad Fallatah; Abdulaziz Almalik; Ali H Alhasan; Khalid Shah; Jeffrey M Karp
Journal:  Sci Adv       Date:  2020-07-22       Impact factor: 14.136

View more
  2 in total

1.  Combination of mesenchymal stem cells and three-dimensional collagen scaffold preserves ventricular remodeling in rat myocardial infarction model.

Authors:  Rida-E-Maria Qazi; Irfan Khan; Kanwal Haneef; Tuba Shakil Malick; Nadia Naeem; Waqas Ahmad; Asmat Salim; Sadia Mohsin
Journal:  World J Stem Cells       Date:  2022-08-26       Impact factor: 5.247

Review 2.  Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements.

Authors:  Dinko Mitrečić; Valentina Hribljan; Denis Jagečić; Jasmina Isaković; Federica Lamberto; Alex Horánszky; Melinda Zana; Gabor Foldes; Barbara Zavan; Augustas Pivoriūnas; Salvador Martinez; Letizia Mazzini; Lidija Radenovic; Jelena Milasin; Juan Carlos Chachques; Leonora Buzanska; Min Suk Song; András Dinnyés
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.